Sign in
FDMT Stock Price, Chart, Stats & News
4D Molecular Therapeutics, Inc.
Save
451.67M
Market cap
–
Current P/E
–
Forward P/E
FDMT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -14.04% |
Operating margin | -187.24% |
Pretax margin | -164.43% |
Net margin | -164.43% |
Effective tax rate | – |
ROA | -24.72% |
ROE | -31.75% |
D/E | 0.04x |
Interest coverage ratio | – |
FDMT valuation
P/E | – |
P/S | 5.59x |
P/B | 1.07x |
P/CF | -4.95x |
P/FCF | -4.32x |
P/OCF | -4.95x |
PEG | -0.12x |
EV multiple | -3.23x |
About
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.
Similar securities
Based on sector and market capitalization
Report issue